Gelesis

Gelesis is developing a breakthrough smart pill (GS100) to fulfill the unmet need for a product that can safely result in significant weight loss. GS100 was developed for overweight and obese individuals, as well as for patients with impaired fasting glucose and diabetes who would particularly benefit from weight reduction but for whom weight loss is often a challenge. A safe, effective treatment for obesity and diabetes (two of the leading public health epidemics in the world) would have a major impact on the lives of millions of people suffering from these debilitating diseases. Gelesis has generated extensive in vitro, in vivo and human data supporting the efficacy and safety of GS100. Gelesis is headquartered in Boston, Massachusetts and was founded by PureTech Health and a group of leading obesity researchers. Gelesis is led by a strong management team, with expertise in business, materials science, and medicine. Our scientific advisory board and clinical advisors are key opinion leaders in the obesity field.